Started as a clinical thermometer producer in Japan in 1921, Terumo is a comprehensive medical device player with a diversified global revenue... Show more
The RSI Oscillator for TRUMY moved into overbought territory on February 03, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 65 cases where TRUMY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TRUMY advanced for three days, in of 292 cases, the price rose further within the following month. The odds of a continued upward trend are .
TRUMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on January 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TRUMY as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for TRUMY turned negative on January 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRUMY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for TRUMY entered a downward trend on February 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.075) is normal, around the industry mean (11.448). P/E Ratio (22.836) is within average values for comparable stocks, (149.436). Projected Growth (PEG Ratio) (2.173) is also within normal values, averaging (2.437). Dividend Yield (0.014) settles around the average of (0.017) among similar stocks. P/S Ratio (2.809) is also within normal values, averaging (111.001).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. TRUMY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRUMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Industry PharmaceuticalsOther
A.I.dvisor indicates that over the last year, TRUMY has been loosely correlated with HOCPY. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if TRUMY jumps, then HOCPY could also see price increases.
| Ticker / NAME | Correlation To TRUMY | 1D Price Change % | ||
|---|---|---|---|---|
| TRUMY | 100% | -1.66% | ||
| HOCPY - TRUMY | 51% Loosely correlated | +3.34% | ||
| SSMXY - TRUMY | 45% Loosely correlated | -0.43% | ||
| SMTI - TRUMY | 43% Loosely correlated | -6.80% | ||
| OLYMY - TRUMY | 40% Loosely correlated | -1.24% | ||
| AZTA - TRUMY | 39% Loosely correlated | -1.65% | ||
More | ||||
| Ticker / NAME | Correlation To TRUMY | 1D Price Change % |
|---|---|---|
| TRUMY | 100% | -1.66% |
| Pharmaceuticals: Other industry (107 stocks) | 27% Poorly correlated | -0.12% |
| Pharmaceuticals industry (380 stocks) | 21% Poorly correlated | -0.30% |